In a recent work published in BME Frontiers, a collaborative study by researchers from Griffith University, Queensland University of Technology, University of Queensland, and Nanjing Stomatological ...
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck. Mechanisms of resistance to anti-PD1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback